Skip to main content

Site notifications

XIIDRA (Shire Australia Pty Ltd)

Product name
XIIDRA
Date registered
Evaluation commenced
Decision date
Approval time
216 working days (255)
Active ingredients
lifitegrast
Registration type
NCE/NBE
Indication

XIIDRA (eye drops) is indicated for the treatment of moderate to severe dry eye disease in adults for whom prior use of artificial tears has not been sufficient.

Help us improve the Therapeutic Goods Administration site